Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Artenimol→

Artenimol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
71939-50-9
Molecular formula
C15H24O5
Molecular weight
284.35 g/mol
Drug class
Dihydroartemisininartemisinin-derived antimalarial endoperoxide
Mechanism of action
The endoperoxide bridge is activated by haem/iron within Plasmodium parasites, generating reactive radicals that damage parasite proteins and other cellular components. It is used in combination regimens to reduce resistance development.
Indications / reported uses
  • Treatment of uncomplicated Plasmodium falciparum malaria as a component of fixed-dose artemisinin-based combination therapy (for example, dihydroartemisinin–piperaquine); not recommended as monotherapy

Sources: WHO Guidelines for malaria · NLM MeSH — Dihydroartemisinin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Artenimol Environmental Risk Assessment (ERA) (the Artenimol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.